VERO Biotech’s Nitric Oxide System for Rebreathing Anesthesia Approved

VERO Biotech has gained FDA approval for its second generation tankless Genosyl inhaled nitric oxide (iNO) delivery system for use with rebreathing anesthesia, the first system approved for breathing and rebreathing.

Rebreathing anesthesia offers significant advantages as it helps patients retain moisture and body heat as loss of body heat and moisture can be key complications of anesthesia, especially for smaller patients such as infants and children. Rebreathing also allows for lower use of fresh gas, reducing cost as well as reducing environmental pollution from anesthetic gas waste.

The system allows anesthesiologists to set the iNO dose without adjusting fresh gas flow or anesthetic agent and facilitates the transition between the intensive care unit and the operating room for ventilated patients, the company said.